Get the Stockscreener App
23.62
0.81%
0.19
Edgewise Therapeutics Inc stock is traded at $23.62, with a volume of 2.03M.
It is up +0.81% in the last 24 hours and up +11.57% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$23.43
Open:
$24.01
24h Volume:
2.03M
Relative Volume:
1.90
Market Cap:
$2.50B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-15.24
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
+0.13%
1M Performance:
+11.57%
6M Performance:
+53.18%
1Y Performance:
-16.09%
1-Day Range:
$22.77
$25.00
1-Week Range:
$22.77
$25.00
52-Week Range:
$10.60
$35.50
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
23.62 | 2.48B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics (NASDAQ:EWTX) Trading 4% HigherStill a Buy? - MarketBeat
Braidwell LP Raises Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Bellevue Group AG Boosts Stock Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Wall Street analysts’ outlook for Edgewise Therapeutics Inc (EWTX) - setenews.com
Discipline and Rules-Based Execution in EWTX Response - news.stocktradersdaily.com
Schroder Investment Management Group Has $1.98 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Analysts Offer Insights on Healthcare Companies: Nano-X Imaging (NNOX), Edgewise Therapeutics (EWTX) and BioNTech SE (BNTX) - The Globe and Mail
EWTX SEC FilingsEdgewise Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.4%Should You Sell? - MarketBeat
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
XTX Topco Ltd Takes Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Sio Capital Management LLC Acquires New Position in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics Advances with Phase 1 Study of EDG-15400 - MSN
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics (Nasdaq: EWTX) issues inducement option for 26,250 shares at $26.04 - Stock Titan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edgewise Therapeutics (EWTX) Stock Analysis Report | Financials & Insights - Benzinga
Handelsbanken Fonder AB Increases Stake in Edgewise Therapeutics, Inc. $EWTX - Defense World
Geode Capital Management LLC Raises Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Acquires 42,753 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Is Edgewise Therapeutics Inc a good long term investmentHigh Dividend Yield Stocks & High Yield Portfolio Growth - earlytimes.in
[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan
Edgewise Therapeutics Appoints Christopher Martin to Board - MSN
Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat
Will Edgewise Therapeutics (EWTX) Gain a Commercial Edge With Its New Board Appointment? - Sahm
Edgewise Therapeutics adds commercial biotech exec Martin to board - Investing.com
Edgewise Therapeutics adds commercial biotech exec Martin to board By Investing.com - Investing.com Nigeria
Edgewise Therapeutics Appoints Christopher Martin as Director - TradingView
[8-K] Edgewise Therapeutics, Inc. Reports Material Event | EWTX SEC FilingForm 8-K - Stock Titan
Edgewise Therapeutics appoints commercial biotech executive Christopher Martin to its Board of Directors - marketscreener.com
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin To Its Board Of Directors - TradingView
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors - WV News
What is the fair value of Edgewise Therapeutics Inc. stock now2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
What recovery options are there for Edgewise Therapeutics Inc.Quarterly Performance Summary & Accurate Trade Setup Notifications - newser.com
Multi asset correlation models including Edgewise Therapeutics Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Exit strategy if you’re trapped in Edgewise Therapeutics Inc.Earnings Overview Report & Short-Term High Return Ideas - newser.com
How to track smart money flows in Edgewise Therapeutics Inc.July 2025 Breakouts & Safe Entry Point Identification - newser.com
Will Edgewise Therapeutics’ (EWTX) New CFO Mark a Shift in Its Commercial Strategy? - Yahoo Finance
Edgewise Therapeutics (EWTX): Assessing Valuation After Clinical Progress and New CFO Appointment - Sahm
What valuation multiples suggest for Edgewise Therapeutics Inc. stockPrice Action & Free Technical Confirmation Trade Alerts - newser.com
Shareholder Carruthers Files To Sell 70,000 Of Edgewise Therapeutics Inc [EWTX] - TradingView
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):